-
Mashup Score: 5Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation - 2 year(s) ago
AbstractContext. Zoledronate is used to prevent bone loss following denosumab discontinuation but its efficacy differs among studies.Objective. To test if the d
Source: OUP AcademicCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Bilateral atypical femoral fractures during denosumab therapy in a patient with adult-onset hypophosphatasia - 3 year(s) ago
Summary Hypophosphatasia (HPP) is a rare and under-recognised genetic defect in bone mineralisation. Patients presenting with fragility fractures may be mistakenly diagnosed as having osteoporosis and prescribed antiresorptive therapy, a treatment which may increase fracture risk. Adult-onset HPPhypophosphatasia was identified in a 40-year-old woman who presented with bilateral atypical femoral…
Source: EDM Case ReportsCategories: Endocrinology, Latest HeadlinesTweet-
This Endocrine Society of Australia (@EndoSocAus) member case report identifies bilateral atypical femoral fractures during #denosumab therapy in a patient with adult-onset #hypophosphatasia https://t.co/N8ugZWNpFe https://t.co/PLyBZsmjt9
-
-
Mashup Score: 0Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis - 3 year(s) ago
To compare bone mineral density (BMD) changes after 12 months of treatment with denosumab or bisphosphonates in postmenopausal women with severe osteoporosis after stopping teriparatide therapy.
Source: Endocrine PracticeCategories: Endocrinology, Latest HeadlinesTweet-
September Issue of #EndocrinePractice Switching to #Denosumab or #Bisphosphonates After Completion of #Teriparatide Treatment in Women With Severe Postmenopausal #Osteoporosis https://t.co/9ieXbgptr4
-
-
Mashup Score: 0Switching to denosumab or bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis - 3 year(s) ago
Our findings from clinical practice showed that after stopping teriparatide, one year of sequential treatment with denosumab yielded greater spinal BMD gains as compared to a bisphosphonate in women with severe postmenopausal osteoporosis. These real-world data might add to optimal clinical management of similar patients after teriparatide discontinuation.
Source: Endocrine PracticeCategories: Endocrinology, Latest HeadlinesTweet-
In Press at #EndocrinePractice Switching to #denosumab or #bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis #EndoTwitter https://t.co/kjA7Fgysgr
-
-
Mashup Score: 1Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone - 3 year(s) ago
A 41-year-old man presented with a 2-month history of progressive vision loss and headaches. MRI revealed a large sellar tumour with suprasellar extension, which was deemed a probable pituitary macroadenoma (figure A, B). The patient underwent transsphenoidal surgery because of visual field defects and headaches. Histological analysis after surgery revealed a giant cell tumour of bone (GCTB) and…
Categories: Endocrinology, Latest HeadlinesTweet-
#Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell #tumour of #bone https://t.co/et4QAKW95I #Cancer #WorldCancerDay #IAmAndIWill #FREE to read
-
-
Mashup Score: 3
To our knowledge, this is the first clinical trial of an investigational drug for osteolysis that shows tissue-specific biological efficacy. These results justify the need for future trials that target earlier-stage disease to test for clinical efficacy in reducing the need for revision surgery.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW Research: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial at @sheffielduni @SheffieldHosp examined the effect of #denosumab on osteolytic lesion activity after total hip #arthroplasty https://t.co/6l3GCwmNeh #LancetRheumatology https://t.co/DKtLFvhIcX
-
-
Mashup Score: 0Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone - 3 year(s) ago
A 41-year-old man presented with a 2-month history of progressive vision loss and headaches. MRI revealed a large sellar tumour with suprasellar extension, which was deemed a probable pituitary macroadenoma (figure A, B). The patient underwent transsphenoidal surgery because of visual field defects and headaches. Histological analysis after surgery revealed a giant cell tumour of bone (GCTB) and…
Categories: Endocrinology, Latest HeadlinesTweet-
Clinical Picture: #Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone https://t.co/wnjYZg5KJ6 #pituitary #Neurosurgery #FREE to read
-
-
Mashup Score: 1Serious Infection Risk Not Significantly Higher With Denosumab vs Alendronate in Osteoporosis - Infectious Disease Advisor - 4 year(s) ago
Researchers assessed the serious infection risk for denosumab vs alendronate in real-world practice.
Source: Infectious Disease AdvisorCategories: Infectious Disease, Latest HeadlinesTweet-
Researchers assessed the serious infection risk for #denosumab vs alendronate in real-world practice. https://t.co/2UQ56W1Yxl
-
-
Mashup Score: 0Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone - 4 year(s) ago
A 41-year-old man presented with a 2-month history of progressive vision loss and headaches. MRI revealed a large sellar tumour with suprasellar extension, which was deemed a probable pituitary macroadenoma (figure A, B). The patient underwent transsphenoidal surgery because of visual field defects and headaches. Histological analysis after surgery revealed a giant cell tumour of bone (GCTB) and…
Categories: Endocrinology, Latest HeadlinesTweet-
Clinical Picture: #Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone https://t.co/sKgJNZF2ME #pituitary macroadenoma
-
-
Mashup Score: 0Delayed Denosumab Injections Associated With Increased Vertebral Fracture Risk - Endocrinology Advisor - 4 year(s) ago
Researchers estimated risk for fracture among patients receiving denosumab with delayed subsequent doses vs those who received doses on time.
Source: Endocrinology AdvisorCategories: Endocrinology, Latest HeadlinesTweet-
Compared with on-time dosing, delayed administration of subsequent #denosumab doses by >16 weeks is associated with increased risk for #vertebralfracture. https://t.co/QTdCU24HAu
-
Endocrine Feedback Loop Podcast | Listen to Amal Shibli-Rahhal, MD and John Bilezikian, MD, PhD (hon) as they discuss this #JCEM article @EndoSocJournals (https://t.co/jM9l6ydnA7) on #Zoledronate to maintain BMD gains after #Denosumab (https://t.co/GCyFlPoUir). https://t.co/XHy1XdDNCO